Live Breaking News & Updates on வின்சென்ட் இதயம் மையம்
Stay updated with breaking news from வின்சென்ட் இதயம் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
email article A novel approach to heart failure with preserved ejection fraction (HFpEF) that takes a page from fibrotic lung disease appeared to pay off, with a reduction in myocardial fibrosis, the phase II PIROUETTE trial showed. The antifibrotic drug pirfenidone (Esbriet, approved for idiopathic pulmonary fibrosis) reduced myocardial extracellular volume by 1.21 percentage points more than placebo over 52 weeks (0.7% decline vs 0.5% increase, P=0.009). A treatment effect of that magnitude would be expected to translate to a 9% to 28% reduction in heart failure hospitalization or death, based on recent observational studies, reported Christopher Miller, MBChB, PhD, of the University of Manchester in England, at the virtual American College of Cardiology (ACC) meeting. ....
May 15, 2021 For immediate post-MI patients, sacubitril/valsartan (Entresto; Novartis) does not significantly decrease the risk of heart failure (HF) or CV death compared with an ACE inhibitor, the PARADISE-MI trial shows. sacubitril/valsartan is superior to an ACE inhibitor in patients who have symptomatic HF with reduced ejection fraction when it comes to reducing both HF events and total mortality, PARADISE-MI fell short by missing its primary endpoint of a 15% reduction in events needed to demonstrate superiority of the angiotensin receptor neprilysin inhibitor (ARNI) over an ACE inhibitor, ramipril, in this acute MI population. Nevertheless, there was a 10% reduction in the sacubitril/valsartan group and positive reports of reduced events from investigators who participated in the large multinational trial. ....
s After the Pandemic series, we asked our editorial board members to discuss what significant and lasting effects the COVID-19 pandemic will have on medicine and the delivery of healthcare. Here, we interview Mary Minnow Walsh, MD, heart failure cardiologist at St. Vincent Heart Center in Indianapolis, Indiana, and past president of the American College of Cardiology. Can you share an anecdote about a patient of yours and how the pandemic influenced their situation? What was the outcome? Walsh: We had a patient, for whom we had a donor heart, decline transplantation during the early part of the pandemic. He was overwhelmed by the possible risk to him and the prospect that visitor restrictions would result in him being in the hospital without family. He is stable and still awaiting transplant. ....
March 05, 2021 Cardiologists and other healthcare professionals may be shocked by the specifics set out in this week’s news of a $45 million lawsuit against Oregon Health & Science University (OHSU) and a former anesthesia resident. But they’re also not surprised. Jason Campbell, MD, who is widely known as the TikTokDoc and whose dance moves brought joy during the COVID-19 pandemic, is accused in the suit of sending explicit texts, photos, and messages as well as sexual assault. What stands out is here not the months-long, all-too-common ordeal described in the lawsuit. Rather, it’s the time line showing that the woman, an employee at the Portland VA Medical Center, where Campbell occasionally worked, had to repeatedly push for OHSU to put the behavior to an end. ....